Efficacy and safety of gefapixant, a P2X<sub>3</sub> receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
Merck Sharp & Dohme LLC
Lorcan P McGarvey; Surinder S Birring; Alyn H Morice; Peter V Dicpinigaitis; Ian D Pavord; Jonathan Schelfhout; Allison Martin Nguyen; Qing Li; Anjela Tzontcheva; Beata Iskold; Stuart A Green; Carmen La Rosa; David R Muccino; Jaclyn A Smith; COUGH-1 and COUGH-2 Investigators